Group Administrators Office
Canadian Cancer Trials Group Recognition Awards
|The Canadian Cancer Trials Group's Central Operations and Statistics Office is very pleased to announce that we are now seeking nominations for the following Recognition Awards:
Dr. Ralph Meyer Phase III Young Investigator Award
The Ralph Meyer Young Investigator Award is presented annually to any MD, fellow, PhD, within 3 years of certification / first faculty appointment or current fellow who has either spent time at Canadian Cancer Trials Group's Central Office, worked on Phase III projects with Disease Site Committees / Endpoint Committees / Working Groups, or who has contributed significantly to the conduct of a Phase III trial at a centre.
Canadian Cancer Trials Group Founder's Award: Dr. Joseph Pater Excellence in Clinical Trials Research Award
The Founder's Award is presented annually to an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This award honours an Investigator whose excellence in clinical trials research has provided techniques, information or concepts that will direct the future of the oncology research community and the Canadian Cancer Trials Group.
Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award
The Elizabeth Eisenhauer Young Investigator Award is presented annually to any MD, fellow, or PhD, within 3 years of certification / first faculty appointment, or current fellow who has either spent time at Canadian Cancer Trials Group's Central Office, worked on projects with the Investigational New Drug Program or who has contributed significantly to the conduct of an IND trial at a centre.
Additionally, Central Office will be awarding two team awards:
Phase III and IND Program Team Awards
Metrics regarding trial-specific accrual both overall and for 2014, local activation timelines, and also compliance metrics are compiled by the Central Operations and Statistics Office. This information will be reviewed by the IND Executive for the IND Trial Team Awards and by the Clinical Trials Committee for Phase III Trial Team Awards. Individual trial teams from member centres will be acknowledged for their efforts and dedication to the success of clinical trials. There is no external nomination process.
These awards, acknowledging the hard work of our Investigators, CRAs, and Pharmacists (e.g. fastest activating site, most accrual, fastest data submission while still remaining compliant, and so on), will be presented during Friday afternoon's Plenary Session at Spring Meeting.
All nominations should be sent to Alison Urton, Group Administrator, at email@example.com by Friday, February 20, 2015. For complete information, including the nomination process, please see this link ...